Healthcare / BiotechnologyTaipei Exchange
$397.50
+13.50 (+3.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-1.0B · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.7%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.36B · FCF $-1.45B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-1.36B | $-1.36B | $-744.3M | $-687.2M | $-313.5M |
| EBITDA | $-2.61B | $-2.61B | $-1.31B | $-1.07B | $-465.8M |
| EPS | — | — | -9.47 | -9.22 | -4.34 |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 |
| Current Ratio | 58.18 | 58.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.45B | $-1.45B | $-1.03B | $-1.01B | $-383.4M |
| Returns | |||||
| ROE | -12.7% | -12.7% | -26.1% | -32.2% | -25.4% |
| Valuation | |||||
| P/B | 3.07 | 3.07 | 3.79 | 3.96 | 9.84 |
| Growth & Yield | |||||
| EPS Growth | — | — | -2.7% | -112.6% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+190.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.47 → n/d
Residual
+190.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.